profit from every $100 of sales.
$0$100
Quince Therapeutics
$31.00+5.77% today
-97.6% in 1 year
1-year low $16.001-year high $3,520.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Quince Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$84.0 million of profit last year.
SalesProfit
Quince Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Quince Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Quince Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -51 | -27 | -36 | -50 | |
| -51 | -27 | -36 | -50 | |
| -52 | -31 | -57 | -84 | |
| -15.40 | -8.40 | -13.10 | -16.80 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 104 | 168 | 114 | 94 |
| Cash | 45 | 21 | 6 | 6 |
| Total debt | 0 | 14 | 15 | 18 |
| Total liabilities | 3 | 83 | 84 | 129 |
| 101 | 85 | 30 | -36 | |
| 3 | 4 | 4 | 5 | |
| -40.0% | -21.7% | -63.6% | – | |
| -51.4% | -36.9% | -188.5% | 235.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -44 | -18 | -32 | -41 | |
| 0 | 0 | 0 | 0 | |
| -44 | -18 | -32 | -42 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 17 | 5 | 5 | 5 |
Valuation
- –
- –
- –
- 7.0×
- –
- –
- 0.2×
- -129.5%
- -260.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -280.9%
- 39.9%
- 1,823.5%
- -124.1%
- -301.3%
- –
Growth
- –
- –
- −29.9%
- –
- +13.9%
Financial health
- 0.3×
- 0.02
- 1.1%
- –
- 2.92
- 2.92
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.59 | -1.30 | +54.6% |
| Apr 10, 2026 | -4.30 | -0.18 | −2,292.9% |
| Nov 12, 2025 | -0.25 | -0.20 | −25.0% |
| Aug 11, 2025 | -0.34 | -0.28 | −21.4% |
| May 13, 2025 | -0.34 | -0.24 | −41.7% |
| Mar 24, 2025 | -0.28 | -0.19 | −47.4% |
| Nov 13, 2024 | -0.13 | -0.17 | +25.0% |
| Aug 13, 2024 | -0.18 | – | – |
News
Is getting a wedding band from Quince a bad idea? It’s a third of the price of a local jeweler.MarketWatch · Oct 26, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
44No pass
Philip Fisher
40No pass
Peter Lynch
62Pass
Joel Greenblatt
100Pass
Charlie Munger
41No pass
Terry Smith
35No pass
Questions about Quince Therapeutics
Is Quince Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Quince Therapeutics AI analysis
What does Quince Therapeutics do?
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. It is in Biotechnology.
Does Quince Therapeutics pay a dividend?
No. Quince Therapeutics does not pay a dividend at the moment.
Is Quince Therapeutics stock halal?
No. Quince Therapeutics does not pass our halal screen: its debt is 57% of its market value, at or above the 33% limit. How we check
How has Quince Therapeutics stock done over the past year?
Down 97.6% over the past twelve months, to $31.00. It traded between $16.00 and $3,520.00 and is 99.1% below its high.
Who are Quince Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Quince Therapeutics's.
Prices: daily closes to Nov 6, 2026. Fundamentals: company reports via invest-like data.